Research progress of new anti-eosinophilic drugs in asthma
Chu Xiaojuan
Yang Wenting
Tang Liantao
Li Xiangkui
Fu Chenkun
Tian Xin
Cheng Yiju
Abstract：Asthma is one of the common chronic non-communicable diseases in the world today,which is characterized by variable gas obstruction,causing dyspnea and wheezing.Eosinophilic airway inflammation is often considered to be the most influential diagnosable feature of chronic airway disease.Over the past decade,multiple monoclonal antibodies have been developed targeting this characteristic.Mainly including anti interleukin-5(IL-5)or IL-5 receptors α(mepolizumab,razumab,and benazizumab),IL-13(lebrikizumab and tralokinumab),IL-4 receptor α(monoclonal antibodies against dupilumab),immunoglobulin E(omalizumab),and thymic stromal resistance lymphatic hormone(tezepelumab)of monoclonal antibodies.This article reviews the pathogenesis of asthma and the progress of new anti-eosinophil drugs in the treatment of asthma.
Keywords：AsthmaAnti-eosinophil drugsEosinophilic airway inflammation
Publication Date：2024-06-08
Online Publishing Date：2026-09-14(First online date of this platform, not the publication date of the document)
Pages：4( 924-927 )